Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Summary

To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.

Timeline

Start

2020-09

Primary completion

2024-09

Completion

2024-12-05

Outcome

Outcome not reported

Stopped: “Similar clinical trials showed not very encouraging results, which made us decide, after several modifications to the protocol and numerous difficulties encountered, to abandon the trial.”

Drugs

Indications